ANAB

46.6301.62%
JP

John P. Schmid

Independent Director

Mr. John P. Schmid, M.B.A., serves as an Independent Director of BlossomHill Therapeutics, Inc. since May 15, 2026. Mr. Schmid has served as a member of the boards of directors of AnaptysBio, Inc., a publicly held biotechnology company (AnaptysBio), since June 30, 2015, Design Therapeutics, Inc., a publicly held biopharmaceutical company, since November 2020, Bright Peak Therapeutics AG, a privately held biopharmaceutical company, since March 2025, Helix Acquisition Corp. III, a special purpose acquisition company (Helix Acquisition Corp III), since January 22, 2026 and First Tracks Biotherapeutics, Inc., a publicly held biopharmaceutical company, as an Independent Non-Employee Director since April 2026 and following its spin out from AnaptysBio. Mr. Schmid serves as chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid has strategic, operational and financial expertise in the life sciences industry. Mr. Schmid previously served as Lead Director at Poseida Therapeutics, Inc. since July 2018 until its acquisition by Roche in January 2025. He served as the Lead Independent Director at Xeris Biopharma Holdings, Inc. since October 2021 until June 04, 2025 and as the Lead Independent Director at Xeris Pharmaceuticals, Inc. since February 2019 until October 05, 2021 and its Independent Non-Executive Director since September 7, 2017 until October 05, 2021. Mr. Schmid previously served as Chairman of the Board of Directors at Blacksmith Medicines (formerly known as Forge Therapeutics, Inc.) from May 2017 until April 2024, as a Director of Neos Therapeutics, Inc. since June 11, 2015 until its acquisition by Aytu BioSciences, Inc. in March 19, 2021, as an Independent Director of Helix Acquisition Corporation, a special purpose acquisition company, since October 19, 2020 until April 2022, Helix Acquisition Corporation II from February 13, 2024 to August 2025 and as a Director of Patara Pharma, Inc. from May 5, 2016 to August 2018. From September 2013 to June 2015, Mr. Schmid served as Chief Financial Officer and Principal Accounting Officer of Auspex Pharmaceuticals, Inc. until its sale to Teva Pharmaceutical Industries Ltd in May 2015. From June 2004 to September 2013, Mr. Schmid co-founded Trius Therapeutics, Inc. (formerly, Rx3 Pharmaceuticals Inc.) where he served as Chief Financial Officer, Principal Accounting Officer and Secretary until its merger with Cubist Pharmaceuticals, Inc. in September 2013. Mr. Schmid served as Chief Financial Officer of Vessix Vascular, Inc. Mr. Schmid served as Chief Financial Officer of GeneFormatics, Inc. from 1998 until its acquisition by Cengent Therapeutics in May 2003, where he then served as the Chief Financial Officer of Cengent Therapeutics. From 1995 to 1998, Mr. Schmid served as Chief Financial Officer of Endonetics Inc. (acquired by Medtronic, formerly, Akos Biomedical). He served as President and Board Member of the San Diego Venture Group. He served as an Associate with Idanta Partners. Prior to Idanta, he served as Vice President at HomeFed Bank and a Financial Analyst for Manufacturers Hanover in New York and as a Financial analyst for J. P. Morgan. Mr. Schmid received his B.A. in economics from Wesleyan University and his M.B.A. from the University of San Diego.

Positions